[Thymus hyperplasia after chemotherapy in a case of Hodgkin's disease].
Andreopoulos
D
D
Klinik für Diagnostiche Radiologie, RWTH Aachen.
Klose
K C
KC
Glöckner
W M
WM
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D005260:Female; D006037:Glyoxal / Q000009:adverse effects; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects; D011238:Prednimustine / Q000009:adverse effects; D011241:Prednisone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D013952:Thymus Hyperplasia / Q000139:chemically induced* / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed; D014747:Vinblastine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
D001761:Bleomycin; D011344:Procarbazine; D006037:Glyoxal; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011238:Prednimustine; D007069:Ifosfamide; D011241:Prednisone
Thymushyperplasie nach Chemotherapie eines Morbus Hodgkin.